Can small doses of psychedelics help us reconnect with ourselves, process difficult emotions, and approach life differently? Here's what I've experienced and what the research is beginning to reveal.
Microdosing has been a game changer for me recently.
Over the past two years, I've had to navigate some challenging family dynamics that have brought old trauma to the surface and led to periods of deep depression I hadn't experienced in a couple of decades.
My usual meditation and yogic practices, which have been foundational in my life for more than twenty years, weren't getting me to the core of what was happening. I could observe my thoughts, regulate my breathing, and apply the tools I had developed over years of practice, yet something deeper remained unresolved.
I was carrying grief and anguish that I hadn't fully processed.
I began microdosing to explore whether it might help shift my mood and give me a different relationship with what I was experiencing.
What I've noticed is a greater capacity to stay connected to my heart, feel the grief I had been holding, and allow some of that emotional weight to move. It's as though there's more room inside me for difficult feelings without immediately closing down around them.
My circumstances haven't magically changed. The challenges are still there. But I find myself able to maintain a more positive outlook much of the time, while remaining open to feelings that might otherwise lead me to withdraw or shut down.
I don't want to overstate what has happened or suggest that my experience will be the same for everyone. But it has been meaningful enough to make me curious about the relationship between psychedelics, emotional processing, and our capacity for change.
That curiosity has extended into my work.
As part of my 12-week Purpose, Power, & Presence program, I explored the possibility of incorporating an optional microdosing component for participants. What I've observed in the group has been encouraging: greater openness, empathy, understanding, and connection, alongside what appears to be a more compassionate relationship each man has with himself.
These are my observations, not the results of a controlled study. Other elements of the program, including group connection, shared practice, and the willingness to engage honestly, may also be contributing.
Still, the experience has prompted me to look more closely at what microdosing is, what science can tell us about it, and where we need to remain discerning.
What is microdosing?
Microdosing refers to taking a small amount of a psychedelic substance, commonly psilocybin or LSD, with the intention of experiencing subtle effects without a full psychedelic experience.
Psilocybin is the naturally occurring psychedelic compound found in certain mushrooms. After ingestion, the body converts it into psilocin, which interacts with serotonin receptors in the brain, particularly the 5-HT2A receptor. LSD also acts on serotonin receptors, although its pharmacology and duration of action differ.
Serotonin is involved in regulating mood, perception, sleep, appetite, and several other functions. Psychedelics influence these systems in ways that can alter perception, cognition, and emotional experience.
A microdose is generally intended to remain below the threshold of a pronounced psychedelic experience. However, there is no universally accepted definition of a microdose, and the line between subtle effects and noticeable psychoactive effects isn't the same for everyone.
The term describes an intention more than a guaranteed experience.
Some people report subtle changes in mood, attention, creativity, or their ability to engage with emotions. Others notice little difference. Some experience anxiety, restlessness, physical discomfort, or unwanted changes in perception.
An important distinction is that microdosing is different from a full psychedelic session. Research involving a substantial dose of psilocybin in a carefully prepared, supported clinical setting cannot automatically tell us what repeated low doses will do.
These are related areas of research, but they involve different experiences, protocols, and questions.
What does the science say about microdosing?
Interest in microdosing has grown considerably, with people exploring it for mood, focus, creativity, emotional well-being, and personal development.
The scientific picture, however, is more complicated than many popular accounts suggest.
A 2024 rapid review examined 19 placebo-controlled studies of LSD and psilocybin microdosing. The researchers found evidence that low doses can produce measurable changes in aspects of physiology, brain activity, subjective experience, and cognition. They also highlighted significant limitations in the existing research, including small samples, limited dose ranges, and methodological challenges.
The findings suggest that microdosing isn't necessarily just a placebo effect. At the same time, they don't establish that it reliably improves mood, cognition, or mental health in everyday use.
This distinction matters because the popular conversation often moves quickly from evidence that a substance affects the brain to the assumption that those changes necessarily produce meaningful benefits.
They aren't the same thing.
Neuroplasticity: Can psychedelics help the brain change?
Neuroplasticity is the nervous system's capacity to change its structure and function in response to experience. It allows us to learn, adapt, form new associations, and modify patterns of thought and behavior.
Researchers are investigating whether psychedelics influence processes associated with neuroplasticity, including changes in neural signaling, connectivity, and the formation of connections between neurons.
Some laboratory and animal studies have found that psychedelic compounds can influence pathways associated with neuronal growth and plasticity. Human research has also identified changes in brain activity and connectivity following psychedelic exposure.
Microdosing studies have produced some findings consistent with changes in neural processing. But the evidence does not yet establish that microdosing reliably produces lasting increases in neuroplasticity in humans, or that such changes necessarily translate into better mental health.
Even if a substance creates conditions in which the brain may be more adaptable, that doesn't determine what gets learned or which patterns change.
Our experiences, relationships, habits, and environment still matter.
The more useful question may not be simply whether the brain can change, but what kinds of change become possible, for whom, and under what conditions.
Mood and emotional regulation
One of the most common reasons people explore microdosing is the hope of feeling less depressed, anxious, or emotionally stuck.
My own experience has centered on grief and the capacity to remain open to difficult feelings. Rather than simply trying to feel better, I've found value in being more able to stay present with what hurts.
That distinction is important. Emotional well-being isn't always about eliminating uncomfortable feelings. Sometimes it involves developing a greater capacity to experience them without becoming overwhelmed, shutting down, or organizing our lives around avoiding them.
Some microdosing studies have reported changes in mood and emotional experience. Other controlled studies have found smaller, inconsistent, or no meaningful improvements in the outcomes people hoped to change.
Expectations can also influence what people experience and how they interpret it. Because psychedelics can make their effects recognizable, blinding participants in placebo-controlled studies can be difficult. This makes it harder to separate the pharmacological effects of a substance from expectation and context.
There is more encouraging evidence for psilocybin administered in structured clinical research for depression, often alongside psychological preparation and support. A 2025 meta-analysis of six randomized controlled trials involving 427 participants found that psilocybin-assisted therapy reduced depression ratings more than comparison conditions, with effects observed through approximately six weeks.
Those findings are promising, but they concern supported psilocybin-assisted therapy, not microdosing. They don't establish that microdosing treats depression.
The distinction is particularly important for anyone experiencing persistent or severe depression. Microdosing shouldn't be treated as a proven substitute for appropriate mental health care.
Creativity, focus, and cognitive performance
Microdosing has also attracted attention from artists, entrepreneurs, and people looking for greater creativity or productivity.
Anecdotal reports describe improved concentration, more flexible thinking, and a greater ability to approach familiar problems from new angles.
Researchers have investigated these claims, but controlled studies haven't established reliable, broad improvements in creativity or cognitive performance. Some experiments have found subtle effects on particular tasks, while others have found no improvement or changes that could be considered disadvantages.
A person might feel more creative without producing more original work. Someone might feel unusually focused while performing no better on an objective measure of attention.
Subjective experience matters, but it isn't identical to measurable performance.
For me, the more interesting possibility is that a shift in mood or perspective might make it easier to approach something differently. Whether that translates into lasting changes in creativity, problem-solving, or behavior remains an open question.
Addiction and compulsive behavior
Psychedelics are also being investigated for their potential role in addiction treatment.
Clinical studies of psilocybin-assisted therapy have explored smoking cessation and alcohol use disorder, among other areas. Some findings have been encouraging, although the evidence remains developing and the treatments studied generally involve more than simply taking small doses.
We should be careful not to transfer these findings directly to microdosing. There is currently insufficient evidence to conclude that microdosing reliably helps people overcome addiction.
Still, the broader research raises important questions about how shifts in perspective, emotional processing, motivation, and a person's relationship with their own behavior might contribute to recovery.
Compulsive behaviors often persist despite our conscious intentions to change. Understanding the emotional, relational, and environmental patterns that maintain them remains important, whether or not psychedelics are part of the picture.
A substance cannot do the work of recovery on someone's behalf.
What dosage is considered a microdose?
There is no single, scientifically established microdose that is appropriate for everyone, and no universally accepted protocol for using psilocybin or LSD this way.
In research, doses are defined according to the particular substance, study design, and outcome being investigated. Studies of LSD and psilocybin use different protocols, so their quantities aren't interchangeable. Psilocybin-containing mushrooms also vary in potency, making mushroom weight an unreliable indicator of the exact amount of active compound.
The term microdose generally refers to an amount intended to produce subtle effects rather than a full psychedelic experience. But even a small amount can produce noticeable or unwanted effects, and what feels subtle to one person may feel quite different to another.
It is also important to distinguish a research protocol from a recommendation for personal use. Researchers control the substance, dose, screening, and study conditions as carefully as possible. Those conditions may be very different from using an unregulated product at home.
For these reasons, I wouldn't treat a particular quantity or dosing schedule circulating online as a proven therapeutic protocol. There is not yet sufficient evidence to establish an optimal microdose, an ideal frequency, or a long-term regimen for improving mood or emotional well-being.
Anyone considering psychedelic use should understand the legal context, potential risks, and relevant medical considerations rather than assuming that a dose is safe simply because it is described as small.
What are the risks?
The term microdose can make an experience sound inherently low-risk. That isn't a reliable assumption.
A small dose may still produce unwanted psychological or physical effects. A 2025 systematic review of microdosing studies identified reported adverse effects including increased blood pressure, anxiety, and cognitive impairment. Researchers also noted that the evidence is limited by inconsistent reporting and the short duration of many studies.
Other considerations include:
- Psychological effects: Anxiety, agitation, confusion, or an unexpectedly intense experience.
- Cardiovascular effects: Temporary increases in heart rate or blood pressure.
- Medication interactions: The effects of combining psychedelics with medications and other substances aren't fully understood. A qualified clinician or pharmacist can help assess relevant risks.
- Mental health history: People with a personal or family history of psychotic disorders or bipolar disorder, particularly mania, may face additional risks and should seek qualified medical guidance.
- Uncertain potency: Unregulated products may vary in strength, composition, and purity.
- Long-term uncertainty: We have limited evidence about the safety and effects of repeated microdosing over extended periods.
Psychedelics aren't appropriate for everyone. They can also be difficult to navigate when someone is already in a vulnerable psychological state.
If you're experiencing significant depression, suicidal thoughts, mania, or other serious mental health symptoms, seek appropriate professional care rather than relying on microdosing to manage them.
A thoughtful approach to this subject requires curiosity alongside caution.
My experience: creating room for grief
What has mattered most to me isn't an increase in productivity or a sense that I've somehow become a better version of myself.
It's the feeling of having more room for my own experience.
When difficult family dynamics activated old wounds, I found myself returning to emotional territory I hadn't visited in many years. The practices that usually help me stay grounded weren't reaching the heart of what was happening.
I don't see this as a failure of meditation or yoga. These practices have given me a great deal. But no single approach reaches everything, and sometimes the strategies that help us regulate ourselves can also become ways of staying at a distance from feelings that need to be experienced more fully.
My experience with microdosing has seemed to make it easier to approach some of that grief. I've felt more able to remain open in situations where I might otherwise contract, withdraw, or become consumed by difficult emotions.
That doesn't mean the substance has resolved the underlying issues. It doesn't mean every difficult feeling has a hidden lesson or that pain should be transformed into something positive.
It means that, in my experience, something has shifted in my capacity to be with what is happening.
I can feel sadness without losing sight of everything else in my life. I can acknowledge the difficulty of my circumstances while remaining connected to love, gratitude, and possibility.
For me, that is meaningful.
I also recognize that I cannot isolate the role of microdosing from everything else happening in my life. My contemplative practices, relationships, and ongoing efforts to understand myself are still part of the picture.
I share this because personal experience can be a valuable starting point for inquiry. It simply isn't a substitute for research, and it doesn't establish what will happen for someone else.
Connection, community, and the relational dimension
The group experience has been another important part of my exploration.
In my Purpose, Power, & Presence program, I've observed what appears to be a greater willingness among participants to speak honestly, listen to one another, and meet each other with compassion.
The men seem more willing to be seen in their uncertainty and vulnerability. I've also noticed moments of greater self-acceptance, where a man can acknowledge something difficult about himself without immediately retreating into defensiveness or self-judgment.
These observations are encouraging, but I can't attribute them to microdosing alone. The program itself creates a context for connection through shared practices, reflection, accountability, and the experience of being witnessed by others.
That context matters.
Many of the patterns we struggle with are relational. We learn to hide parts of ourselves to gain acceptance, suppress needs to preserve connection, or protect ourselves from experiences of shame and rejection. These adaptations can persist long after the circumstances that produced them have changed.
A meaningful relationship can create opportunities to experiment with something different: expressing a feeling without being shamed, receiving feedback without being rejected, or acknowledging a mistake without losing our sense of worth.
Whether microdosing contributes to that process, and how, requires more research. But the relational dimension deserves attention in its own right.
We don't develop in isolation, and lasting change often involves more than an individual experience or a shift in brain chemistry.
Integration: what happens after the experience?
One of my central interests in this work is integration: how we bring what we experience into the way we actually live.
A change in mood or perspective can be meaningful, but it doesn't automatically change our habits, relationships, or decisions. Feeling more open doesn't guarantee that we'll communicate more honestly. Recognizing a familiar pattern doesn't mean we'll respond differently when it appears again.
The work is to notice what has shifted and explore whether that shift can become part of our everyday lives.
That might mean having a conversation we've been avoiding, allowing ourselves to feel grief rather than immediately distracting ourselves, or recognizing when an old defense is shaping how we respond to someone we love.
It may also mean discovering that an experience hasn't changed much at all, or that its effects are more complicated than we expected.
Integration requires honesty about all of these possibilities.
I don't believe every experience needs to produce a revelation. Nor do I believe that every difficult emotion needs to be resolved. Sometimes the work is simply to remain present, develop a little more understanding, and practice responding with greater awareness.
If microdosing has a meaningful role for someone, I suspect that role needs to be understood within the larger context of their life, their relationships, their health, and the practices that help them change.
The substance is only one part of that picture.
Psychedelics in Oregon: access and responsibility
Oregon has become an important part of the evolving conversation about psychedelic access.
In 2020, voters approved Measure 109, establishing a regulated framework for psilocybin services. Under this model, adults aged 21 and older can access psilocybin through licensed service centers, following preparation with a licensed facilitator and consuming the product at the service center under supervision.
This is different from general legalization or unrestricted access. Psilocybin remains federally controlled, and Oregon's regulated services framework does not authorize people to purchase psilocybin products through that system and take them home for unsupervised use. Oregon also changed its broader drug-decriminalization policy in 2024, so it would be inaccurate to describe psychedelics generally as legalized or decriminalized in the state.
Oregon's framework is significant because it creates a regulated setting for preparation, administration, and integration. It also raises important questions about affordability, access, practitioner training, safety, and how emerging research should inform practice.
For me, the larger opportunity is to move beyond stigma and simplistic claims in either direction. Psychedelics shouldn't be dismissed without examining the evidence, nor should they be promoted as universal solutions.
We need better research, honest communication about uncertainty, thoughtful safeguards, and a willingness to learn from both positive and difficult experiences.
An invitation to stay curious
My recent experience with microdosing has opened new questions for me about grief, emotional openness, and the ways we work with patterns that seem resistant to change.
I'm encouraged by what I've experienced, and by the broader scientific interest in psychedelics. I'm also aware of how much we still don't know, particularly about microdosing, its long-term effects, and who is most likely to benefit or experience harm.
I don't see psychedelics as a replacement for the deeper work of living. Relationships, embodiment, contemplative practice, honest self-reflection, and the willingness to take responsibility for our choices all remain important.
What interests me is whether these substances may, for some people and in some circumstances, create opportunities to approach experience differently.
Sometimes the most meaningful change isn't that our circumstances become easier. It's that we become more capable of meeting them without abandoning ourselves.
That's what I'm continuing to explore.
This article reflects my personal experience and a developing area of research. It is not medical advice or a recommendation to use psychedelics. Microdosing has not been established as a safe and effective treatment for depression or other mental health conditions.